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Abstract
When treating opioid addiction, multidisciplinary treatment is highly recom-
mended, but pharmacotherapy plays a key role. Although the ideal goal is to achieve 
complete abstinence, an elevated percentage of opioid addicts requires maintenance 
substitution therapy. In the first section of this chapter, we will focus on the cur-
rent pharmacological interventions to treat opioid addiction, such as methadone, 
buprenorphine, and naltrexone. Thanks to these medications, people are able to go 
back to their normal lives, by preventing withdrawal symptoms, reducing craving, 
and increasing their adherence to psychotherapy. In the second section, based on 
the evidence that addiction induces neuroadaptive changes in several neurotrans-
mission systems, we focus on the wide range of possible pharmacological develop-
ments at the preclinical and clinical levels, which in recent years have increased 
considerably.
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1. Introduction
Addiction is a chronic and multifactorial disorder characterized by compulsive 
drug seeking and use, despite its harmful consequences. Chronic opioid use induces 
profound molecular and behavioral changes, inducing long-lasting changes in 
brain plasticity [1]. During the use of the drug, reward and motivation circuits are 
modified, and new learning and memories are created in relation to the pleasurable 
effects of the drug and the context in which it is consumed [2]. These memories 
will later be responsible for the vulnerability to relapse even after a long period of 
withdrawal. In order to restructure these memories and avoid relapse and crav-
ing to opioids, the first recommended approach currently consists in combining 
psychotherapy with pharmacological substitution therapy [3]. Opioid addiction is 
currently a major medical and social problem, and its abuse and recreational use 
have been declared an epidemic in the USA [4, 5], with more than 90 people dying 
from an opioid overdose every day [6].
Opioids are highly addictive because they induce euphoria (positive reinforce-
ment) and the cessation of a chronic use produces dysphoria [7]. The non-medical 
opioid use is a major public health challenge, making opioids the second most used 
illicit drug in the USA [8].
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The use of opioids has increased 10- to 14-fold in the last 20 years, including 
those taken under supervision and recreational use [9].
In relation to this, opioids are one of the most commonly misused medica-
tions. Although it is usually prescribed to treat pain, its abuse has serious medical 
consequences. According to NIDA (National Institute on Drug Abuse, NIH), 
misuse of prescription drugs is defined as taking a medication in a manner or 
dose different than has been prescribed, either for a medical complaint, such as 
pain, or to feel euphoria [2]. The number of opioid prescriptions has increased 
significantly since the early 1990s [10], with this easier access to the drug being 
one of the reasons for the high prevalence of opioid misuse [9]. However, other 
factors can contribute to the problem, such as the lack of information about the 
addictive properties of prescription opioids, which are perceived as less harmful 
than illicit opioids [11, 12]. Regardless of the primary causes, there has been a 
dramatic increase in the number of treatment admissions for addictive disorders 
related to prescription opioids, as well as the associated overdose deaths in the 
past 15 years [8, 13, 14].
Pharmacological treatments are essential for initiating and sustaining effec-
tive patient-, public health, and system-level interventions to reduce opioid-
related morbidity and mortality [15]. In the specific case of opioid use disorders, 
pharmacotherapy is strongly recommended as a part of an integrated approach, 
also including psychosocial interventions, psychotherapy, or relapse prevention 
programs [16]. Until the 1960s, the opioid addiction treatment was only oriented 
towards abstinence, but then the potential action of methadone as a maintenance 
treatment for opioid addiction was evaluated [17]. Currently, although complete 
abstinence continues to be the best possible outcome, the most common option is 
life-long substitution therapy. While the currently approved medications improve 
the outcomes, relapse rates are still high, and pharmacotherapy is not effective in all 
patients [18].
The final goal of the treatment is to reduce the risk of illicit opioid use, over-
dose or infections, as well as the general improvement of the individuals’ quality 
of life [15]. The available pharmacological interventions prevent the appear-
ance of withdrawal symptoms and reduce craving, also increasing adherence 
to the psychotherapy. First, we will address the three different approved drugs 
on the market [19]. Although the rate of success, measured by maintenance of 
abstinence, has been greatly improved with the existing treatments, there is still 
room for further improvement. In a second part of this chapter, we will also refer 
to new treatments under development, both in preclinical models and in clini-
cal trials. These new drugs are focused on different neurotransmission systems, 
which are altered by the neuroadaptive changes induced during the addictive 
process.
2. Current approved pharmacological treatments for opioid addiction
2.1 Opioid agonist therapies
The great percentage of withdrawn patients who relapse into drug use [20] 
makes opioid maintenance therapy the first-line treatment in most cases. Ideal 
agents for substitution maintenance therapy are those with a high affinity for μ-type 
opioid receptors showing long-term action. Methadone and buprenorphine, as 
potent and long-acting opioid agonists, are usually prescribed for opioid substitu-
tion therapy, and both constitute the most effective treatments for opioid depen-
dence [22].
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2.1.1 Methadone
Methadone is a safe, efficient, and effective treatment for heroin addiction 
[23]. This μ-opioid receptor agonist was introduced in the USA by Eli Lilly and 
Company as an opioid analgesic in 1947. Methadone maintenance treatment began 
at the Rockefeller Hospital (1965) with the aim to develop an effective and long 
action pharmacotherapy that targeted opioid receptors. In these initial clinical 
trials, patients received safe doses (20–40 mg) once a day, and over time, the dose 
was adjusted to avoid withdrawal symptoms and reduce craving [17]. Since 1964, a 
great number of studies have documented the safety, efficacy, and effectiveness of 
methadone pharmacotherapy for heroin addiction [23].
The National Institutes of Health (NIH) at the end of the 1990s supported 
methadone maintenance pharmacotherapy for heroin addiction. Nowadays, half 
of the problematic opiate users are under maintenance treatment, with more 
than 60% receiving methadone [24]. Elevated retention rates with a noteworthy 
decrease of illicit opiate use have been observed under methadone maintenance 
treatment [21, 25–27]. In addition, there are reductions of other associated 
problems such as intravenous drug use, crime [28–30], and improvement of social 
functioning [31]. Later studies reported that prolonged methadone maintenance 
normalized the immune system function in heroin addicts [32], as well as the 
altered stress response [33]. Methadone is also well suited with performance 
of complex cognitive tasks [34]. Regarding its efficacy, according to a recent 
Cochrane meta-analysis, methadone and buprenorphine appear to be equally 
effective [35].
Regardless of the positive effects of methadone, one of the main difficulties of 
methadone maintenance treatment is the stigma accompanying the methadone 
clinics. In order to solve this, maintenance programs aim to rehabilitate patients by 
reassigning addicts from a traditional clinic to a medical office for ongoing treat-
ment. The concept of medical maintenance carefully emulates the treatment of 
chronic diseases, such as insulin-dependent diabetes [32].
On the other hand, there are specific drug interactions of methadone [36], for 
example, the antituberculosis agent rifampin or the anticonvulsant phenytoin 
[37–39]. Methadone can also inhibit gonadotropin-releasing hormones, lower-
ing testosterone levels [40, 41]. Finally, another recognized effect of methadone 
is the QT prolongation [42]. Patients who undergo prolonged QT intervals must 
switch to a treatment with buprenorphine, which does not affect it [43]. Several 
countries, including Germany and Austria, have alternative treatments for opioid 
maintenance, such as Levomethadone (purified methadone) [44], which exerts its 
pharmacologic effects mainly via agonism of μ-opioid receptor.
2.1.2 Buprenorphine
Buprenorphine and the combination buprenorphine-naloxone were also intro-
duced as a possible treatment for opioid use disorder. This medication is character-
ized by a better side effect profile, lower abuse potential, and good availability when 
compared to methadone [3]. Buprenorphine is a μ-receptor partial agonist that 
can reduce opiate cravings, prevent opiate withdrawal, but at the same time blocks 
the effects of other more powerful opiates [45]. As partial agonist, buprenorphine 
presents a safety profile with respect to other μ-opioid-receptor agonists and 
can be more easily adjusted to the desired effect [46]. Although buprenorphine 
can be the first-line medication over methadone to treat opioid addiction, as it 
has considerable less abuse potential, its efficacy is limited when treating severe 
opioid use disorders. Due to the displacement of a stronger opioid by a weaker 
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one, buprenorphine can precipitate withdrawal symptoms [33, 47]. To increase the 
adherence to this treatment, patients should be at least in mild withdrawal [48].
To avoid diversion, buprenorphine is usually combined with the specific 
opioid antagonist, naloxone. In 2006, it was introduced in the European market 
as a sublingual combination tablet. Several works have established the efficacy 
of buprenorphine-naloxone as a maintenance medication [49–51] not only for 
prescription opioids but also for heroin addiction [52, 53]. Numerous meta-
analyses have determined that buprenorphine produces successful results in heroin 
dependence, with no deficiency with respect to being abstinent of illicit opioid 
use [54, 55]. However, methadone was found to be superior to buprenorphine in 
overall treatment retention [56]. Buprenorphine therapy not only improves the 
overall individuals’ quality of life but also decreases overcrowding in emergency 
departments [57, 58].
From a pharmacological point of view, buprenorphine has important advantages 
over methadone besides the lower risk of overdose [41, 59]. It is preferable for 
treatment of opioid dependence in those patients with HIV/AIDS [60, 61] and for 
pregnant opioid users [62]. On the other hand, when buprenorphine is combined 
with respiratory depressants, such as alcohol or benzodiazepines, it results in seda-
tion, coma, or even death [63]. Furthermore, patients who do not know about the 
pharmacology of buprenorphine and use additional opioids seeking a “high” are at 
risk of an overdose when the effects of buprenorphine wear off [55, 64, 65].
2.2 Opiate antagonist therapies
The antagonist therapy blocks or reduces a biological response by binding to 
and blocking a receptor rather than activating it like an agonist. Naloxone and 
naltrexone, the opioid antagonist treatments most accepted and commonly used, 
prevent and reverse opioid effects by mainly blocking the μ-opioid receptor. Both 
are employed for quick detoxification if there is an overdose and to prevent relapse 
[66]. Naloxone is a short-acting non-selective opioid antagonist that reverses an 
opioid overdose. Overdose is a common event for those who use opioids and is 
the leading cause of death in this population [67, 68]. It quickly crosses the blood-
brain barrier and can reverse morphine-induced respiratory depression within 
1–2 min [69].
Different studies support the effectiveness of community-based naloxone train-
ing and distribution programs in reducing overdose deaths [24, 70, 71]. Naloxone is 
considered a safe drug to use with little probability of complications, since it has no 
agonistic activity at the μ-opioid receptor [23]. Since opioid abuse has been declared 
an epidemic in the USA [4], naloxone has been made more accessible to the relatives 
of opioid users, which decreases potentially fatal overdoses around 30–40% [72, 73].
Naltrexone is an opioid receptor antagonist that blocks the euphoric and 
reinforcing effects of opioids consumption, being mainly used for detoxification 
programs [74–77]. However, the main disadvantage of the use of this antagonist is 
the low rate of adherence to this treatment, since less than 20% of patients continue 
opioid antagonist treatments after several months [78]. Nevertheless, with highly 
motivated patients or dependent people who cannot be included in the methadone 
program, naltrexone maintenance therapy can be proposed as a successful approach 
for treating opioid addiction [79]. Furthermore, it has the advantage of not gen-
erating tolerance and/or dependency [80]. In the last years, a new intra-muscular 
depot formulation of naltrexone has been approved, being useful in reducing the 
days-of-heroin-use and relapse rate compared with a placebo [81, 82]. This depot 
naltrexone is taken once monthly, and several studies have shown good outcomes 
compared to placebo in decreasing craving in naltrexone-treated patients [83]. 
5Present and Future Pharmacological Treatments for Opioid Addiction
DOI: http://dx.doi.org/10.5772/intechopen.82443
These extended-release naltrexone formulations address the compliance problems 
that are often found with oral administration [84]. However, a recent comparative 
study shows that the extended-release naltrexone presents more difficulties in 
terms of induction and ongoing care with respect to other buprenorphine products, 
such as the sublingual film of buprenorphine-naloxone [85].
Nevertheless, to date, the extended-release naltrexone is, together with metha-
done and buprenorphine, the most recommended pharmacotherapy for opioid use 
disorders, as it has shown superiority with respect to placebo treatment and coun-
seling [83, 86, 87].
3. New pharmacological therapies in development of opiate addiction
Drug addiction induces significant changes in numerous neurotransmission 
systems [1], which became new therapeutic targets to treat opioid addiction. 
Therefore, new pharmacological targets are constantly being developed to improve 
opiate addiction treatment. This second part of the review will offer an overview of 
the most promising agents under development and we will also discuss the recent 
advances in neuroinflammation and the pharmacogenetics field.
3.1 Drugs acting on opioid receptors
With the aim of increasing the efficacy and adherence of treatments, numer-
ous studies are testing new approaches to the currently approved medications. 
For example, the newest buprenorphine subdermal implant called probuphine 
[88], which was approved by the FDA in May 2016, is prescribed to those patients 
who have achieved a sustained clinical stability with low-to-moderate doses of a 
transmucosal buprenorphine-containing product.This implant guarantees non-
fluctuating blood levels of buprenorphine continuously for 6 months improving 
patient compliance [89].
There is growing interest in the slow-release oral morphine (SROM), as a poten-
tial effective candidate for maintenance treatment [90–92]. This medication is given 
once daily, and it suits those individuals who cannot tolerate methadone, respond 
poorly to other available treatments, or show a prolonged QT [93–95]. However, the 
last Cochrane meta-analysis reported that there is not enough evidence to confirm 
the effectiveness of SROM for opioid maintenance, as only three inconclusive stud-
ies exist [96].
Tramadol, a reuptake inhibitor of serotonin and norepinephrine, produces a 
metabolite that moderately acts as a μ-opioid receptor agonist [97]. Recent clinical tri-
als have demonstrated for tramadol the same level of treatment retention and opioid 
withdrawal symptom suppression as buprenorphine, suggesting that this is a promis-
ing and valuable medication [98, 99]. However, although it has been used in the 
management of acute withdrawal, its use for maintenance treatment as a harm reduc-
tion approach has not been assessed systematically. A recent pilot study of tramadol 
on long-term maintenance in patients with opioid use disorders showed that most of 
them were able to achieve and maintain abstinence for at least 6 months [100].
3.2 Dopaminergic compounds
It is well known that dopamine (DA) neurotransmission is a common mecha-
nism of drugs of abuse, although the use of DA compounds has not been success-
ful [22]. Numerous preclinical studies have tested the efficacy of different DA 
antagonists. Acute administration of the DA D3 receptor antagonist SB277011 
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reduces the reinforcing effects of different drugs of abuse and diminishes opiate 
withdrawal syndrome [101]. The well-known antipsychotics, aripiprazole (par-
tial DAD2 and 5HT1A agonist and a 5HT2A antagonist) and risperidone (atypical 
antipsychotic), block context-dependent induced relapse. Risperidone also inhib-
its reinstatement into heroin seeking due to environmental cues but fails to block 
relapse induced by priming doses [102]. In the same line, aripiprazole inhibits 
the conditioned place preference (CPP) induced by morphine [103]. An ongoing 
clinical trial is evaluating aripiprazole effects to prevent relapse to cocaine use in 
patients being treated with methadone, as they could return to cocaine consump-
tion, even when they are involved in a drug treatment program [104].
3.3 Glutamatergic compounds
Preclinical studies show that reinstatement of morphine CPP is mainly medi-
ated through glutamatergic neurotransmission [105]. NMDA receptors modulate 
nociceptive signals in conjunction with opioid receptors, and after continuous mor-
phine treatment, both receptors suffer a desensitization, which mediate analgesic 
tolerance [22]. Therefore, NMDA receptor antagonists can prevent the development 
of morphine tolerance. Ifenprodil, an NMDA antagonist, prevents the development, 
maintenance, and reinstatement of morphine-induced CPP, as well as reinstatement 
of heroin-seeking self-administration [106].
Another well-known NMDA antagonist is memantine. Animal and human 
studies have shown positive results in reducing opiate withdrawal and preventing 
relapse [107–109]. However, clinical trials have not found significant differences in 
treatment retention, heroin consumption, or craving with respect to placebo [110]. 
Although memantine administered in combination with naltrexone can improve 
the emerging symptoms during the early phase of treatment, this combination did 
not induce significant improvement in preventing relapse [111].
The nitric oxide synthase (NOS) is a neural retrograde messenger molecule 
involved in several opioid effects. It has been reported that NOS upregulation 
takes place during the development of opioid dependence [112] and its inhibition 
blocks opioid dependence [113, 114]. In addition, administration of NOS inhibitors 
diminishes the development of morphine-induced CPP [106].
3.4 GABA compounds
Baclofen is a GABA-B receptor agonist approved for spasticity treatment, and 
early preclinical studies suggested that it could promote abstinence from a variety 
of drugs of abuse [115], such as cocaine, ethanol, nicotine, and methamphet-
amine [116–119]. Baclofen also reduces morphine withdrawal signs in morphine-
dependent animals [120, 121] and disrupts reconsolidation of conditioned reward, 
facilitating the extinction of the morphine-induced CPP [122]. Assadi and cowork-
ers [123] performed a clinical trial to evaluate the possible benefit of baclofen in the 
maintenance treatment of opioid addicts and found that the baclofen group pre-
sented increased treatment retention being superior to placebo in terms of opiate 
withdrawal syndrome and depressive symptoms.
An effective add-on therapy combined with methadone or buprenorphine is pre-
gabalin and gabapentin, which are approved for treatment of epilepsy, neuropathic 
pain, or fibromyalgia [124]. These medications do not act directly on GABA recep-
tors or transporters [125] but modulate the α2-delta subunit of calcium channels, 
preventing the release of neurotransmitters like glutamate [126]. Both medications 
prevent opioid tolerance and dependence and reduce withdrawal symptoms in 
humans and preclinical models [127–129].
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3.5 Cholinergic compounds
Numerous studies have demonstrated that the cholinergic system is also impli-
cated in opioid addiction, as chronic morphine administration is associated with 
changes in gene expression in the cholinergic system, and it increases cholinergic 
neurons in the laterodorsal tegmental nucleus. Administration of nicotinic antago-
nists reduces withdrawal symptoms in rodents [130], which suggests that nicotine 
receptors might be a potential pharmacotherapeutic target for opioid detoxifica-
tion. Furthermore, a relatively recent study evaluated the role of the α4β2 nicotinic 
receptors as a potential therapeutic target to treat morphine dependence [131]. A 
recent clinical trial has evaluated the effects of varenicline, a α4β2 partial agonist 
and α7 full agonist, usually employed for smoking cessation. Varenicline was effec-
tive in opioid detoxification patients, as opioid withdrawal scores decrease with 
respect to those patients receiving a placebo [131].
Cholinesterase inhibitors, currently used to treat Alzheimer’s disease, including 
donepezil, rivastigmine, and galantamine, increase cholinergic activity and can 
be potential therapeutic targets in opioid abuse and dependence treatments [132]. 
Preclinical models have demonstrated that these cholinesterase inhibitors pre-
vented morphine tolerance and attenuated the acquisition and expression  
of morphine CPP [133].
3.6 Cannabinoid compounds
There are many studies suggesting the potential action of the endocannabinoid 
system in opioid dependence [134, 135]. Cannabidiol is a natural active metabolite 
of the Cannabis sativa plant, which is currently being explored for its potential 
anti-addiction properties [135]. It is the second most abundant cannabinoid pres-
ent in the plant [136], and interestingly, it does not bind directly to cannabinoid 
receptors but acts as an inverse agonist at both types CB1 and CB2 [137]. Regarding 
this, cannabidiol has been shown to attenuate the cue-induced reinstatement of 
heroin seeking [138] and reduces the rewarding properties of morphine in rodents 
[139]. There is currently a clinical trial examining the effects of cannabidiol on 
drug craving in abstinent heroin-dependent subjects (ClinicalTrial.Gov identifier: 
NCT02539823). In addition, cannabidiol, when combined with a potent opioid like 
fentanyl, is well tolerated, confirming that cannabidiol would be safe in the case of 
a relapse in abstinent heroin abusers [140].
3.7 Neuroinflammation
The neuroimmune response is an important but relatively poorly understood 
process in the development of drug addiction. Research is now setting up oppor-
tunities for the development of new pharmacotherapies targeting neuroimmune 
dysfunction. Opioids induce direct and indirect adaptations in the peripheral and 
central immune systems [141] with a clear relationship between opioid dependence 
and inflammatory processes [142]. Opioids, such as morphine and heroin, act 
directly on macrophages and lymphocytes, which produce changes in the CNS, 
resulting in neurotoxicity [143–145]. Preclinical models show that chronic mor-
phine treatment increases proinflammatory cytokine levels and overactivates the 
glia [146, 147]. The consequences include dendrite atrophy, abnormal neurogenesis, 
and neurodegeneration [148]. To sum up, opioids act to generate the release of pro-
inflammatory cytokines, which induce the activation of the inflammatory response, 
and finally, this response induces changes in the architecture and functioning of 
the brain. Neuroinflammation derived from opioid consumption is implicated in 
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tolerance and dependence processes based on results obtained in animal models 
[149–151]. Anti-inflammatory cytokines, such as the IL-10, which are well toler-
ated and safe in other inflammatory diseases, could be used as pharmacotherapy 
in addiction [152]. For example, gabapentin upregulates the anti-inflammatory 
cytokine IL-10 in rats [128], thus reducing inflammation. Ibudilast prevents glial 
cell activation, inhibiting production of proinflammatory cytokines (IL1β, IL-6, 
TNF-α), and increases the secretion of anti-inflammatory mediators like IL-10 
[153]. Clinical trials are currently evaluating if this medication, or other glial activa-
tion inhibitors, can prevent opioid withdrawal symptoms [154].
On the other hand, peroxisome proliferator-activated receptors (PPARs) medi-
ate anti-inflammatory and neuroprotective processes [155]. Specifically, PPARγ is 
strongly implicated in reward processing and motivation [156], as they are located 
in VTA DA neurons and modulate DA release [157], which suggests its potential role 
in addiction. Currently, preclinical studies have tested the PPAR-γ agonist piogli-
tazone, an anti-inflammatory medication, as a treatment for opioid dependence, 
attenuating morphine withdrawal syndrome in rats [158].
3.8 Pharmacogenetics and epigenetics
Pharmacogenetics focuses on selecting the most adequate treatment for 
specific patients, based on their genetic profile and thereby increasing the thera-
peutic action of the medication. Its goal is the discovery of gene interactions that 
increase the success rate of treatments [22]. There are variants of gene-encoding 
proteins implicated in opioid pharmacokinetics and pharmacodynamics that 
make the patient respond better or worse to a specific treatment. Most studies 
focus on genes related to the therapeutic response to methadone and buprenor-
phine [159]. For example, two gene interactions are determinant for the response 
to methadone. First, there is the ABCB1, the gene encoding the P-glycoprotein 
efflux transporter, of which methadone is a substrate. People with variants of this 
gene (subjects with a wild-type and 61A haplotype combination or homozygous 
for the 61A) show lower methadone requirements. On the other hand, people with 
the variant 118A/A in μ-opioid receptor 1 gene (MOR1) show higher methadone 
requirements [160]. Regarding buprenorphine, the frequency of the gene poly-
morphism (SLC6A3/DAT1) allele 10 in the DA transporter is much higher in non-
responder individuals [161]. These studies reveal the relevance of considering 
genetic variants when considering treatments with methadone or buprenorphine.
Currently, it is known that it is not only the polymorphisms that we inherit but 
also how they are expressed, what really matters in genetics. Epigenetics studies the 
reversible modifications to chromatin and their potent effects on gene expression 
regulation. Biochemical modifications, such as DNA methylation, histone modifica-
tion, or micro-RNA expression, can change the pattern of the cell’s gene expression 
[162]. Consequently, such epigenetic changes can modify drug efficacy and its 
adverse effects, being necessary to take them into account in clinical pharmacol-
ogy [163]. Currently, the role of epigenetics in personalized pharmacotherapy has 
been under-explored [164]. This field of research has increased scientific interest 
in the last years, as changes in DNA methylation or histone modifications alter gene 
expression, which affects reward, craving, and relapse [165]. For example, in opiate 
addiction, several changes have been reported in the μ-opioid receptor 1 (OPRM1) 
gene expression due to the hypermethylation of this gene’s promoter [166, 167]. 
Increased DNA methylation can be a predisposing factor for the vulnerability to 
heroin addiction or it can be a consequence of it. This is a new and exciting unex-
plored field that could offer promising results in future years.
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4. Conclusion and future directions
Opioid addiction is a chronic relapsing brain disease, being a major medical and 
social problem. In the past 12 years, several countries are suffering a rise in opioid 
consumption, not only in its recreative use but also in opioid prescriptions and 
related misuse and abuse [5]. The high rate of relapse observed in opioid addicts 
forces the use of maintenance therapy with substitution opiates to reduce damage 
and to avoid the consumption of illegal opioids, such as heroin. Although the cur-
rently approved pharmacotherapies for opioid addiction are effective and encour-
age patients to stay in treatment, there is still much room for improvement [168]. 
Methadone, buprenorphine, and extended-release naltrexone are currently the 
most effective treatments to attenuate the illicit intake of opioids and, together with 
psychosocial therapy, constitute the best combination to succeed in the treatment 
[18]. The number of new pharmacological targets is constantly increasing, but fre-
quently, initially promising preclinical studies result in failure in the clinical trials. 
However, we should be optimistic, since great advances have been made in recent 
years, but much remains to be improved in a disease as important and complex as 
opiate addiction.
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